Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with non–small cell lung cancer who respond best to treatment with the PD-L1 inhibitor durvalumab.
Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, discusses a study looking to define a subgroup of patients with nonsmall cell lung cancer (NSCLC) who respond best to treatment with the PD-L1 inhibitor durvalumab.
Findings from the analysis were presented at the Society for Immunotherapy of Cancer (SITC) 31st Annual Meeting & Associated Programs. Overall, the combination of CD8+ and PD-L1+ densities correlated with response and improved overall survival with durvalumab.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More